BIO-TECHNE Corp — Director's Dealing 2020

Jul 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2020-07-06

Reporting Person: Hippel James (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-06	Common Stock	M	21502	$108.49	Acquired	30809	Direct
2020-07-06	Common Stock	S	9571	$270.4532	Disposed	21238	Direct
2020-07-06	Common Stock	S	3781	$271.5333	Disposed	17457	Direct
2020-07-06	Common Stock	S	4947	$272.338	Disposed	12510	Direct
2020-07-06	Common Stock	S	1934	$273.7115	Disposed	10576	Direct
2020-07-06	Common Stock	S	1269	$274.5177	Disposed	9307	Direct
2020-07-07	Common Stock	M	2577	$108.49	Acquired	11884	Direct
2020-07-07	Common Stock	S	414	$270.5567	Disposed	11470	Direct
2020-07-07	Common Stock	S	1663	$271.4019	Disposed	9807	Direct
2020-07-07	Common Stock	S	500	$272.26	Disposed	9307	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-06	Stock Options (Right to Buy)	$108.49	M	21502	Disposed	2022-08-07	Common Stock (21502)	Direct
2020-07-07	Stock Options (Right to Buy)	$108.49	M	2577	Disposed	2022-08-07	Common Stock (2577)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$106.59	2023-08-18	Common Stock (30400)	30400	Direct
Stock Options (Right to Buy)	$106.59	2023-08-18	Common Stock (40533)	40533	Direct
Restricted Stock Units	$		Common Stock (4438)	4438	Direct
Stock Options (Right to Buy)	$125.05	2024-08-09	Common Stock (24460)	24460	Direct
Stock Options (Right to Buy)	$125.05	2024-08-09	Common Stock (32613)	32613	Direct
Restricted Stock Units	$		Common Stock (3383)	3383	Direct
Stock Options (Right to Buy)	$177.32	2025-08-08	Common Stock (18066)	18066	Direct
Stock Options (Right to Buy)	$177.32	2025-08-08	Common Stock (24089)	24089	Direct
Restricted Stock Units	$		Common Stock (3938)	3938	Direct
Stock Options (Right to Buy)	$190.41	2026-08-07	Common Stock (19936)	19936	Direct
Stock Options (Right to Buy)	$190.41	2026-08-07	Common Stock (26581)	26581	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.0000 to $270.9800, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.0000 to $271.9900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.0100 to $272.9500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.2300 to $274.2200, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.2700 to $275.0300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.0700 to $271.0500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.0700 to $271.9000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.0900 to $272.3500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

F11: Fully exercisable.

F12: Options to purchase 10,134 shares vest on 8/18/2017 and options to purchase 10,133 shares vest on each of 8/18/2018, 8/18/2019 and 8/18/2020.

F13: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F14: Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021.

F15: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F16: Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022.

F17: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F18: Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.